Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) Cells.

Belloni E, Martin Padura I, Gerbino E, Orecchioni S, Fusar Imperatore F, Marighetti P, Bertalot G, Giuseppe Pelicci P, Bertolini F.

Sci Rep. 2015 Aug 12;5:13047. doi: 10.1038/srep13047.

2.

The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination.

Rolland Y, Marighetti P, Malinverno C, Confalonieri S, Luise C, Ducano N, Palamidessi A, Bisi S, Kajiho H, Troglio F, Shcherbakova OG, Dunn AR, Oldani A, Lanzetti L, Di Fiore PP, Disanza A, Scita G.

Dev Cell. 2014 Sep 8;30(5):553-68. doi: 10.1016/j.devcel.2014.08.006.

3.

A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination.

Frittoli E, Palamidessi A, Marighetti P, Confalonieri S, Bianchi F, Malinverno C, Mazzarol G, Viale G, Martin-Padura I, Garré M, Parazzoli D, Mattei V, Cortellino S, Bertalot G, Di Fiore PP, Scita G.

J Cell Biol. 2014 Jul 21;206(2):307-28. doi: 10.1083/jcb.201403127.

4.

CDC42 switches IRSp53 from inhibition of actin growth to elongation by clustering of VASP.

Disanza A, Bisi S, Winterhoff M, Milanesi F, Ushakov DS, Kast D, Marighetti P, Romet-Lemonne G, Müller HM, Nickel W, Linkner J, Waterschoot D, Ampè C, Cortellino S, Palamidessi A, Dominguez R, Carlier MF, Faix J, Scita G.

EMBO J. 2013 Oct 16;32(20):2735-50. doi: 10.1038/emboj.2013.208. Epub 2013 Sep 27.

5.

Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer.

Orecchioni S, Gregato G, Martin-Padura I, Reggiani F, Braidotti P, Mancuso P, Calleri A, Quarna J, Marighetti P, Aldeni C, Pruneri G, Martella S, Manconi A, Petit JY, Rietjens M, Bertolini F.

Cancer Res. 2013 Oct 1;73(19):5880-91. doi: 10.1158/0008-5472.CAN-13-0821. Epub 2013 Aug 5.

6.

Human haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endothelium.

Pelosi E, Castelli G, Martin-Padura I, Bordoni V, Santoro S, Conigliaro A, Cerio AM, De Santis Puzzonia M, Marighetti P, Biffoni M, Alonzi T, Amicone L, Alcalay M, Bertolini F, Testa U, Tripodi M.

PLoS One. 2012;7(12):e51109. doi: 10.1371/journal.pone.0051109. Epub 2012 Dec 4.

7.

Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.

Martin-Padura I, Marighetti P, Gregato G, Agliano A, Malazzi O, Mancuso P, Pruneri G, Viale A, Bertolini F.

Neoplasia. 2012 Nov;14(11):1057-66.

8.

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A.

Lab Invest. 2012 Jul;92(7):952-66. doi: 10.1038/labinvest.2012.65. Epub 2012 Apr 30.

9.

The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression.

Martin-Padura I, Gregato G, Marighetti P, Mancuso P, Calleri A, Corsini C, Pruneri G, Manzotti M, Lohsiriwat V, Rietjens M, Petit JY, Bertolini F.

Cancer Res. 2012 Jan 1;72(1):325-34. doi: 10.1158/0008-5472.CAN-11-1739. Epub 2011 Nov 3.

10.

Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.

Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, Hu-Lowe DD, Shaked Y, D'Onofrio A.

Drug Discov Today. 2011 Dec;16(23-24):1052-60. doi: 10.1016/j.drudis.2011.08.007. Epub 2011 Aug 22. Review.

PMID:
21875682
11.

Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.

Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, Redrado M, Calvo A, Bertolini F.

Clin Cancer Res. 2011 Oct 1;17(19):6163-73. doi: 10.1158/1078-0432.CCR-11-0212. Epub 2011 Aug 19.

12.

Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.

Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Maggioni M, Agnelli L, Rebulla P, Prati D, Porretti L.

PLoS One. 2011;6(6):e21369. doi: 10.1371/journal.pone.0021369. Epub 2011 Jun 23.

13.

Circulating perivascular progenitors: a target of PDGFR inhibition.

Mancuso P, Martin-Padura I, Calleri A, Marighetti P, Quarna J, Rabascio C, Braidotti P, Bertolini F.

Int J Cancer. 2011 Sep 15;129(6):1344-50. doi: 10.1002/ijc.25816. Epub 2011 Apr 13.

14.

Sex-related efficiency in NSG mouse engraftment.

Martin-Padura I, Agliano A, Marighetti P, Porretti L, Bertolini F.

Blood. 2010 Oct 7;116(14):2616-7. doi: 10.1182/blood-2010-07-295584. No abstract available.

15.

Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy.

Bertolini F, Marighetti P, Shaked Y.

Biochim Biophys Acta. 2010 Dec;1806(2):131-7. doi: 10.1016/j.bbcan.2010.05.004. Epub 2010 May 31. Review.

PMID:
20685298
16.

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.

Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini R.

Blood. 2009 Dec 10;114(25):5191-200. doi: 10.1182/blood-2008-08-176016.

17.

Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.

Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, Shultz LD, Bertolini F.

Int J Cancer. 2008 Nov 1;123(9):2222-7. doi: 10.1002/ijc.23772.

Supplemental Content

Loading ...
Support Center